SCHEMBL6499469

SCHEMBL6499469

CCCCCC(=O)Nc1cnc2cccc(Cl)c2c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.48
MAPK1 P28482 2/20 0.48
NPC1 O15118 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
DEGS1 O15121 1/20 0.45
EP300 Q09472 1/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CETP P11597 1/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SOAT1 P35610 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501641 0.87 ALDH1A1 (0.47) GLAMAPK1NPC1L3MBTL1DEGS1
SCHEMBL25689106 0.86 RAB9A (0.47) GLAMAPK1NPC1L3MBTL1DEGS1
SCHEMBL25688716 0.82 RAB9A (0.47) NPC1MEN1KMT2ADEGS1ALDH1A1
SCHEMBL6500635 0.81 EP300 (0.57) GLAMAPK1NPC1L3MBTL1DEGS1
SCHEMBL6489167 0.77 GLA (0.54) GLAMAPK1NPC1L3MBTL1DEGS1
SCHEMBL6498462 0.76 GAA (0.51) L3MBTL1DEGS1ALDH1A1GAAHPGD
SCHEMBL2706300 0.75 LMNA (0.47) NPC1KMT2AALDH1A1KDM4EGAA
SCHEMBL29642061 0.73 ALDH1A1 (0.54) GLAMAPK1NPC1L3MBTL1MEN1
SCHEMBL671016 0.73 ALDH1A1 (0.54) GLAMAPK1NPC1L3MBTL1MEN1
SCHEMBL28045299 0.73 MEN1 (0.64) L3MBTL1MEN1KMT2AEP300TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908932-B2 Cancer therapy ICONIX PHARMACEUTICALS, INC. (US) 2005-06-21 US disclosed
US-20030149074-A1 Modulators of phosphoinositide 3-kinase ENTELOS HOLDING CORP. 2003-08-07 US disclosed
WO-2003035618-A2 MODULATORS OF PHOSPHOINOSITIDE 3-KINASE ICONIX PHARMACEUTICALS, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149074-A1 Modulators of phosphoinositide 3-kinase PIK3R1, PIK3R3, PIK3R4 GLA 3551/4885MAPK1 109/4885NPC1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.